Eliezer Katz, MD

Eliezer Katz, MD, is the chief medical officer at Eledon Pharmaceuticals.

Articles by Eliezer Katz, MD

Targeting Costimulatory Pathways With Eliezer Katz, MD

Targeting Costimulatory Pathways in Kidney Transplant With Eliezer Katz, MD

February 5th 2026

Tegoprubart, a CD40L-targeted therapy, may improve long-term kidney transplant outcomes by reducing immune-mediated injury.

2-Year Phase 1b Tegoprubart Maintains Kidney Function in Transplant Recipients With Eliezer Katz, MD

2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients, With Eliezer Katz, MD

ByEliezer Katz, MD

February 3rd 2026

Eliezer Katz, MD, says investigational anti-CD40L therapy tegoprubart shows promise as a non-calcineurin inhibitor option for adult de novo kidney transplant patients

Eliezer Katz, MD

Articles by Eliezer Katz, MD

Targeting Costimulatory Pathways in Kidney Transplant With Eliezer Katz, MD

2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients, With Eliezer Katz, MD

Latest Updated Articles

Trending on HCPLive

Combination Therapy, Adherence, and Access: A PAH Expert Roundtable

Allergists Debate Newer Nonsteroidal Topicals for Atopic Dermatitis

CaRi-Heart Receives FDA De Novo Authorization for Coronary Inflammation

Ritlecitinib Improves Repigmentation in Nonsegmental Vitiligo Phase 3 Data

Why Allergists Aren't Prescribing New Topical Eczema Drugs